How Subcutaneous Amivantamab Fits into EGFR-Mutated NSCLC Management

Narjust Florez, MD, discusses how amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) could be incorporated into routine care for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Florez outlines practical considerations, including time in chair, resource utilization, and patient convenience, that may influence adoption in oncology practice. She also considers how this formulation could ultimately impact the use of the intravenous formulation.